cisplatin,pembrolizumab,enfortumab vedotin,atezolizumab,nivolumab,ipilimumab
astellas,merck,bms,seagen,roche
['muc ,(-much)', 'vedo', 'pembro', 'atezo', ' vedo', 'cisplatin', 'imvigor 130', ' cis ', 'enfortumab', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'carboplatin', 'omg', 'check,mate,901', ' uc,(-ucsd),(-ucsf),']
 discussant highlights #1l chemo + io landscape in #muc given negative phiii imvigor 130 trial. in combining io w/1l chemo, pd-1 appears similar to pd-l1 inh and cis may be better partner than carbo when combined w/io? #gu23 looming is ev+pembro 1l 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope